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Abstract
 
Cadherins are expressed in tissue-restricted patterns and typically mediate homophilic adhesion.
Cadherins also mediate lymphocyte adhesion, providing the opportunity for lymphocyte at-
tachment to parenchymal cells. The best characterized example of lymphocyte adhesion to a
tissue-specific cell adhesion molecule, as opposed to a vascular endothelial adhesion molecule,
is the interaction between integrin 
 
a
 
E
 
b
 
7 
 
on intraepithelial lymphocytes and E-cadherin on epi-
thelial cells. However, the molecular basis for an integrin–cadherin interaction is not well de-
fined. Realization that the cadherin domain adopts a topology similar to the immunoglobulin
(Ig) fold suggested that integrin recognition of E-cadherin might be similar to recognition of Ig
superfamily ligands. Thus, we modeled domain 1 of human E-cadherin and studied the role of
solvent-exposed loops that connect Ig-like core-forming 
 
b
 
 strands. Mutational analyses local-
ized the integrin 
 
a
 
E
 
b
 
7
 
 recognition site to the top of domain 1 at the face formed by the BC and
FG loops, a site distinct from the region recognized in intercellular adhesion molecule
(ICAM)-1, -2, and -3, mucosal addressin cell adhesion molecule 1 (MAdCAM-1), vascular cell
adhesion molecule 1 (VCAM-1), and fibronectin by their integrin ligands. Moreover, the inte-
grin 
 
a
 
E
 
b
 
7
 
 binding site is distinct from the homophilic binding site on E-cadherin. These studies
provide a conceptual basis for integrin–cadherin binding and extend the model that an Ig-like
fold can serve as a scaffold for recognition. 
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Introduction
 
Although several specific adhesion molecules mediate lym-
phocyte adhesion to the vascular endothelium, few molec-
ular interactions have been identified that are involved in
the specific retention of lymphocytes in tissues. The best
characterized tissue-specific interaction is that between in-
tegrin 
 
a
 
E
 
b
 
7
 
 on mucosal T cells, and epithelial (E)
 
1
 
-cadherin
expressed on epithelial cells. E-cadherin has been shown to
mediate T cell–epithelial cell adhesion via 
 
a
 
E
 
b
 
7
 
 in cell–cell
and cell–fusion protein adhesion assays in vitro (1, 2).
Moreover, as the number of intraepithelial lymphocytes
 
(IELs) is markedly reduced in 
 
a
 
E
 
-deficient mice, the
E-cadherin–
 
a
 
E
 
b
 
7
 
 interaction is important in lymphocyte
localization in the epithelium (3). Yet, the molecular basis
for the binding of an integrin and a cadherin is not well un-
derstood.
Integrins are heterodimeric integral membrane proteins
composed of noncovalently associated 
 
a
 
 and 
 
b
 
 subunits.
The integrin 
 
a
 
E
 
 chain contains an inserted domain (I or A)
within its NH
 
2
 
-terminal region (4). The crystal structures
of the A domains of the integrin 
 
a
 
L
 
, 
 
a
 
M
 
, and 
 
a
 
2
 
 chains
have been determined and reveal a metal ion binding site
located at the top of the A domain, (5–9). Five of the six
coordination sites for the divalent cation are contributed
directly or indirectly via water by conserved residues in the
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Abbreviations used in this paper:
 
 E, epithelial; FBS, fetal bovine serum;
HBS, Hepes-buffered saline; HEK, human embryonic kidney; IEL, in-
traepithelial lymphocyte; IgSF, Ig superfamily; ICAM, intercellular adhe-
sion molecule; K562-
 
a
 
E
 
b
 
7
 
, K562 cells stably transfected with 
 
a
 
E
 
b
 
7
 
;
MAdCAM-1, mucosal addressin cell adhesion molecule 1; N, neural; P,
placental; TBS, Tris-buffered saline; VCAM-1, vascular cell adhesion
molecule 1. 
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E
 
b
 
7
 
 Recognition of E-Cadherin
 
A domain that include a linear D-X-S-X-S motif and dis-
continuous threonine and aspartate residues (5–9). In one
crystal structure, the sixth coordination site was provided
by a glutamate residue from an adjacent, symmetry-related
A domain, suggesting a direct role for an acidic residue in
the ligand in coordination of the metal ion (6). It has been
proposed that all integrin 
 
b
 
 chains contain a similar A-like
domain (6). Certain integrin ligands contain acidic residues
that are critical for integrin adhesion and that are present in
solvent-exposed locations accessible for integrin recogni-
tion, generally on loops connecting the strands of Ig-like
domains. For example, recognition of the first Ig domains
of vascular cell adhesion molecule 1 (VCAM-1) and mu-
cosal addressin cell adhesion molecule 1 (MAdCAM-1) re-
quires an acidic residue at the tip of the CD loop on the
lower side of the domain 1 (10–13), and integrin 
 
a
 
L
 
b
 
2
 
 rec-
ognition of intracellular adhesion molecule (ICAM)-1,
ICAM-2, and ICAM-3 requires an acidic residue that is the
last residue of the C strand on the lower side of domain 1
(14, 15).
The 
 
a
 
E
 
b
 
7
 
–E-cadherin interaction is unique among inte-
grin ligands. Cadherins are type 1 integral membrane pro-
teins with five extracellular homologous “cadherin” domains,
a transmembrane region, and a highly conserved cytoplas-
mic tail, and are classically described as calcium-dependent
homophilic cell adhesion molecules important in morpho-
genesis and tissue architecture (16). Although cadherins do
not share detectable sequence homology with Ig super-
famiy (IgSF) members, the structural determination of the
NH
 
2
 
-terminal domains of murine E- and neural (N)-cadherin
by NMR and x-ray crystallography reveals that the overall
topology of the cadherin domain consists of seven 
 
b
 
 strands
that form a 
 
b
 
 barrel and is similar to the Ig fold (17–21).
This realization led us to hypothesize that 
 
a
 
E
 
b
 
7
 
 might rec-
ognize E-cadherin in a manner related to how integrins
recognize their IgSF counterreceptors.
Here, we model the first domain of human E-cadherin
on the murine E-cadherin crystal structure. Through site-
directed mutagenesis, we elucidate the face and specific res-
idues that are the adhesion site for binding the integrin
 
a
 
E
 
b
 
7
 
 and show that this site is distinct from that mediating
homophilic cadherin adhesion. These molecular interac-
tions provide a conceptual basis for the adhesion of leuko-
cytes to parenchymal cells based on the expression of tissue-
specific cadherins.
 
Materials and Methods
 
mAbs. 
 
The following mouse anti–human mAbs were used:
 
a
 
E7-1 (anti-
 
a
 
E
 
b
 
7
 
, IgG2a) (22), 
 
a
 
E7-2 (anti-
 
a
 
E
 
b
 
7
 
, IgG1) (22),
 
a
 
E7-3 (anti-
 
a
 
E
 
b
 
7
 
, IgG1) (22), E4.6 (anti–E-cadherin, IgG1) (23),
HECD-1 (anti–E-cadherin, IgG1; Zymed) (24), and SHE78-7
(anti–E-cadherin, IgG2a; Zymed).
 
Cell Cultures. 
 
Human IEL-496 T cells were derived from
intestinal IELs and maintained as described previously (2, 25).
Human embryonic kidney (HEK)-293-EBNA cells (Invitrogen)
were maintained in DMEM (GIBCO BRL) with 10% fetal bo-
vine serum (FBS) at 10% CO
 
2
 
. Transfectants of the human
 
chronic myelogenous leukemia cell line K562 that express 
 
a
 
E
 
b
 
7
 
(K562-
 
a
 
E
 
b
 
7
 
) were provided by Dr. David Erle (University of
California San Francisco, San Francisco, CA) and maintained as
described previously (26). Human breast epithelial cells MCF-7
(American Type Culture Collection) were grown in DMEM
with 10% FBS at 10% CO
 
2
 
.
 
Construction of Mutated E-Cadherin-Fc Expression Vectors. 
 
Hu-
man E-cadherin-Fc (five extracellular domains of E-cadherin
fused to the Fc portion of human IgG1) (2) was excised from
pCDM8 with EcoRV and NotI and ligated into pBluescript SK
II (pBS; Stratagene). Mutations were introduced by PCR using
pBS-E-cadherin-Fc as a template and Pfu polymerase (Stratagene)
according to the manufacturer’s recommendations with 25 cycles
of 94
 
8
 
C for 1 min, 52
 
8
 
C for 2 min, 72
 
8
 
C for 2 min, and one cycle
at 72
 
8
 
C for 10 min. For mutations with a nearby restriction site,
PCR was performed with one primer complementary to the
wild-type sequence and a second primer containing the mutation
and a restriction site. Mutations to the BC loop were made with a
forward primer complementary near the 5
 
9
 
 end of E-cadherin
(hEprimV 5
 
9
 
-AAG TCA GTT CAG ACT CCA GCC C-3
 
9
 
)
and a reverse primer incorporating the mutation and the MscI site
(hEprimH 5
 
9
 
-AGC TCC TTG GCC AGT GAT GCT GTA
GAA AAC CTT GCC TGC TTT GTC-3
 
9
 
 for E31A,
hEprimAL2 5
 
9
 
-AGC TCC TTG GCC AGT GAT GCT GTA
GAA AAC CTT GCC ATC TTT GTC-3
 
9
 
 for E31D, hEprimT
5
 
9
 
-GCT CCT TGG CCA GTG ATG CGT TAG AAA ACC
GCG CCT TC-3
 
9
 
 for K33A, and hEprimU 5
 
9
 
-GCT CCT TGG
CCA GTG ATG CTG TAG AAA ACC TTG GTA TCT CTG
TCT TT-3
 
9
 
 for KEG30-32RDT). The D44A mutation in the
CD loop was made using a forward primer containing the MscI
site, the D44A mutation (hEprimA 5
 
9
 
-ATC ACT GGC CAA
GGA GCT GCC ACA CCC CCT GT-3
 
9
 
), and a reverse wild-
type primer (hEprimB 5
 
9
 
-CTC CAT TGG ATC CTC AAC
TGC-3
 
9
 
). The E56A mutation in the DE loop was made using a
forward wild-type primer (hEprimG 5
 
9
 
-TAC GGT TTC ATA
ACC CAA CAG ATC CAT TTC TT-3
 
9
 
) and a reverse primer
containing the E56A mutation and the Eco57I site (hEprimJ 5
 
9
 
-
GTT CTC TAT CCA GAG GCT CTG TCA CCT TCA GCC
ATC CTG TTG CTC TTT C-3
 
9
 
).
The other mutations were introduced by overlap extension
PCR (27). First, PCR was performed with a forward primer
complementary to the wild-type sequence near the 5
 
9
 
 end of
E-cadherin (hEprimV) and a reverse primer containing the muta-
tion (hEprimO 5
 
9
 
-TGT AGA AAA CCT TGC CTT CTT
TGT CTT TGT TGG ATG CGA TCT G-3
 
9
 
 for K25A, hE-
primP 5
 
9
 
-TGT AGA AAA CCT TGC CTT CTT TGT CTT
TGG CGG ATT TGA TCT G-3
 
9
 
 for N27A, hEprimQ 5
 
9
 
-TGT
AGA AAA CCT TGC CTT CTT TGT CTG CGT TGG ATT
TGA TCT G-3
 
9
 
 for K28A, hEprimR 5
 
9
 
-TGT AGA AAA CCT
TGC CTT CTG CGT CTT TGT TGG ATT TGA TCT G-3
 
9
 
for K30A, hEprimAA 5
 
9
 
-CTC CAT TGG ATC CTC AAC
TGC ATT CCC GTT GGC TGA CAC-3
 
9
 
 for S83A, hE-
primAC 5
 
9
 
-CTC CAT TGG ATC CTC AAC TGC AGC CCC
GTT GGA TGA CAC-3
 
9
 
 for N86A, and hEprimAE 59-GGT
TAC CGT GAT CAA AAT CTC CAT TGG ATC CGC AAC
TGC-39 for E89A). Concurrently, PCR was performed with a
forward primer complementary to the 59 end of the primer con-
taining the mutation (hEprimS 59-AGA AGG CAA GGT TTT
CTA CAG CAT CAC TGG CCA AGG AGC-39 for K25A,
N27A, K28A, and K30A; hEprimAD 59-GCA GTT GAG GAT
CCA ATG GAG ATT-39 for S83A and N86A; and hEprimAH
59-ACT GGC CAA GGA GCT GAC ACA CCC CCT-39 for
E89A) and reverse primer located downstream (hEprimW 59-1557 Taraszka et al.
TGT TGT CGT TAA CCC CTC ACC-39). A subsequent
PCR reaction was performed using these two overlapping PCR
products as the template and primers at the 59 (hEprimV) and 39
(hEprimW) ends. The PCR products were cleaved with restric-
tion enzymes (NcoI and MscI for K25A, N27A, K28A, K30A,
E31A, E31D, KEG30-32RDT, and K33A; MscI and BamHI for
D44A; PflMI and Eco57I for E56A; and NcoI and SnaBI for
S83A, N86A, and E89A) and ligated into pBS-E-cadherin-Fc.
The PCR-amplified region of each clone was sequenced. The
pBS-E-cadherin-Fc mutants were serially digested, first with
NotI and ScaI, and then with HindIII. The mutated E-cadherin-
Fc insert was ligated into pCEP4 (Invitrogen) and cleaved with
HindIII and NotI. DNA for transfections was prepared using a
Qiagen Plasmid Maxi Kit.
Production of E-Cadherin-Fc Fusion Proteins.  Purified wild-type
E-cadherin-Fc fusion protein was produced as described previ-
ously (2). Mutated and wild-type E-cadherin-Fc fusion protein
was produced by transient transfection of HEK-293-EBNA cells
with 10 mg of pCEP4-E-cadherin-Fc plasmid DNA using the
CaPO4 transfection protocol provided in the Stratagene Mamma-
lian Transfection kit. To produce the cadherin-Fc proteins, trans-
fected cells were grown in DMEM containing 10% ultra-low Ig FBS
(GIBCO BRL). After 5–10 d, the culture supernatants were har-
vested, filtered through a 0.2-mm membrane, and stored at 48C.
ELISA.  Recombinant soluble E-cadherin-Fc fusion proteins
were quantitated in culture supernatants by ELISA. The wells of
Linbro Titertek 96-well plates (ICN Flow Laboratories) were
coated with goat anti–human IgG polyclonal antisera (Zymed) at
10 mg/ml in 35 mM NaHCO3, 15 mM Na2CO3, pH 9.6 for 16 h
at 48C. The wells were washed three times with 200 ml of Tris-
buffered saline (TBS), 1 mM CaCl2, pH 7.4. Subsequently, the
wells were blocked with TBS, 1 mM CaCl2, 1% BSA for 2 h at
room temperature. The wells were washed three times with TBS,
1 mM CaCl2, 0.05% Tween 20. Supernatants from HEK-293-
EBNA cell transfectants were incubated for 2 h at room temp-
erature, and purified wild-type E-cadherin-Fc was used as the
standard. Bound fusion protein was detected with alkaline phos-
phatase–conjugated goat anti–human IgG Fc-specific (Sigma
Chemical Co.) antibody and Sigma 104® phosphatase substrate
(Sigma Chemical Co.). The E-cadherin-Fc fusion proteins were
produced in the range of 10 to 75 mg/ml. To determine the reac-
tivity of the E-cadherin-Fc mutants to E-cadherin mAbs, ELISA
was performed as described above except that 96-well plates were
coated with 1 mg/ml of purified anti–human E-cadherin mAbs,
E4.6 or HECD-1.
Western Blot.  200 ng of wild-type and mutated E-cadherin-Fc
fusion proteins were resolved by SDS-PAGE (7% acrylamide)
under reducing conditions. Proteins were transferred to polyvi-
nylidene difluoride membranes (Immobilon-P; Millipore). Mem-
branes were blocked with 2% gelatin, washed, and then probed
with peroxidase-conjugated goat anti–human IgG Fc (Sigma
Chemical Co.) at 1:100,000. After washing, blots were developed
using enhanced chemiluminescence (NEN Life Science Products).
Adhesion Assays.  Heterophilic adhesion assays were per-
formed as described previously (1, 2). In brief, 96-well plates
were coated with goat anti–human IgG antibody and blocked as
described for ELISA. The wells were washed and subsequently
coated with culture supernatants containing the E-cadherin-Fc
proteins or purified human IgG1 (Calbiochem-Novabiochem
Corp.). IEL-496 or K562-aEb7 cells were labeled with BCECF-
AM (Molecular Probes). The adhesion assay was performed in
Hepes-buffered saline (HBS) with 1 mM MgCl2, 1 mM MnCl2,
1 mM CaCl2, 50 mM dextrose, and 0.1% BSA with 50,000 cells/
well for 10 min at 378C. Labeled cells were detected using a Flu-
orescence Concentration Analyzer plate reader (IDEXX Labora-
tories, Inc.), and the percentage of cells bound was calculated.
The homophilic adhesion assay was performed as above with
the following modifications. MCF-7 epithelial cells were released
from Corning T75 culture flasks and labeled with 10 mg of
BCECF-AM in 5 ml of 0.02% (wt/vol) bovine pancreas trypsin
(Sigma Chemical Co.) in HBS 1 mM CaCl2 for 15 min at 378C.
10 ml of 0.04% (wt/vol) soybean trypsin inhibitor type I-S
(Sigma Chemical Co.) in HBS, 1 mM CaCl2 was added, and the
cells were washed twice with cold HBS without CaCl2. Ho-
mophilic adhesion was carried out in HBS with 1 mM CaCl2,
0.1% BSA, and 50 mM dextrose.
Antibody blocking experiments were performed by preincu-
bation of cells or E-cadherin–Fc-coated wells with 20–40 mg/ml
purified mAb for 10 min at 48C. Adhesion was carried out in fi-
nal concentrations of 10–20 mg/ml purified mAbs.
Statistical Analysis.  Using a two-sided t test and controlling
for plate to plate variability, average values of cell adhesion to
mutated E-cadherin-Fc fusion protein were compared with aver-
age values of cell adhesion to wild-type E-cadherin-Fc to deter-
mine whether adhesion to the mutant was significantly different
from adhesion to wild-type. Using the Bonferroni conservative
adjustment for a confidence limit of 95% with 13 tests, a P value
of 0.05/13 or P # 0.0038 was considered statistically significant.
The analysis was performed using the program “SAS” for UNIX.
Modeling of Human E-Cadherin.  Sequence alignments were
performed using the Genetics Computer Group program PileUp.
Human E-cadherin was modeled based on the murine E-cad-
herin crystal structure (available from the Protein Data Bank,
http://www.rcsb.org/pdb, under accession no. 1EDH) (19). Us-
ing the program “O” (T.A. Jones, Uppsala University, and M.
Kjelgaard, Aahus University), sequence substitution of human
E-cadherin residues into the murine E-cadherin structure was
performed. The side chain conformation of human E-cadherin
residues was chosen to be similar to that of the murine E-cad-
herin residues while potential close contact was avoided.
Results
Sequence Analysis and Modeling of Human E-Cadherin.
The amino acid sequence of the first domain of human
E-cadherin was aligned with that of murine E- and N-cad-
herin, and there did not appear to be any deletions or inser-
tions (Fig. 1 A). Domain 1 of human E-cadherin shares
89% amino acid sequence identity with domain 1 of mu-
rine E-cadherin. Interestingly, all 11 substituted residues are
solvent-exposed based on the crystal structure of the two
NH2-terminal domains of murine E-cadherin (19). There-
fore, the structure of human E-cadherin is predicted to be
very similar to that of murine E-cadherin. As the core
structure of the b barrel is predicted to be highly con-
served, we developed a model of human E-cadherin based
on the murine E-cadherin structure (Fig. 1 B).
This model of human E-cadherin was used to consider
possible interaction sites in cadherin–integrin binding with
special reference to solvent-exposed acidic residues on loop
structures. The seven b strands in the cadherin domain
form two antiparallel b sheets, one formed by b strands D,
E, and B and the other by b strands A, G, F, and C. With-1558 Integrin aEb7 Recognition of E-Cadherin
out the conserved intersheet disulfide bond present in Ig
domains, the b strands in cadherin domains have a more
cylindrical arrangement that has been termed a b barrel.
Loops extend from and connect the b strands, and the ma-
jority of the solvent-exposed residues are located on the
loops. The BC loop is exposed at the top of domain 1 of
E-cadherin, contains a single turn of 310 helix, and as a
whole has a high atomic mobility (18, 19). The BC loop
contains two acidic residues, D29 and E31. Residue D29 is
conserved among cadherin domains (Fig. 1 A). Based on
our model, the side chain of D29 is predicted to point into
the core of the structure and hydrogen bond to Y36. As
D29 may be important in preserving the conformation of
the BC loop, it was not mutated. The side chain of E31 is
solvent-exposed and highly accessible at the tip of the BC
loop, and thus a good candidate for integrin recognition
(Fig. 1 B). The CD loop that protrudes from the lower side
of the domain contains two conserved proline residues
(Fig. 1 A) and assumes a helical structure termed a quasi–b
helix (Fig. 1 B; 18, 19). The central residues of the CD
loop of human E-cadherin, GAD44TP, share a striking
similarity to the integrin binding motif, G/Q I/L E/D S/T
S/P, found in the C strands of ICAM-1, ICAM-2 and
ICAM-3, and in the CD loops of VCAM-1 and MAd-
CAM-1 (28). Based on the similarity to other integrin
binding sites, the solvent-exposed D44 was considered a
good candidate for integrin aEb7 recognition. The DE
loop in E-cadherin points upward and is solvent-exposed
in the central portion of the domain. The side chain of E56
is also solvent-exposed and located at the tip of the DE
loop, and thus also has the potential to be involved in inte-
grin aEb7 recognition (Fig. 1 B). The FG loop is located at
the top of the molecule adjacent to the BC loop (Fig. 1 B),
and there are no negatively charged residues on the tip of
the FG loop of human E-cadherin (Fig. 1 A). The AB and
EF loops are located at the bottom of the cadherin domain
(Fig. 1 B). The acidic residues, E11 and E13, in the AB
loop and acidic residues, D67 and E69, in the EF loop are
predicted to be involved in binding calcium along with res-
idues from the second cadherin domain (Fig. 1 A; 17).
These residues are predicted to be important in domain–
domain interactions, and thus were not selected for muta-
tion as potential integrin binding residues.
Effect of Mutation of the Central Acidic Residues in the BC,
CD, and DE Loops of E-Cadherin on Heterophilic Adhesion to
IELs. We used a recombinant fusion protein consisting of
the five extracellular domains of human E-cadherin fused
to the Fc portion of human IgG1 in order to study E-cad-
herin loop interactions with integrin aEb7 (2). Mutants of
the E-cadherin-Fc fusion protein were produced by tran-
sient transfection of HEK-293 cells as described in Materi-
als and Methods. The concentration of E-cadherin-Fc in
the culture supernatants was determined by ELISA using
purified wild-type E-cadherin-Fc as a standard. Western
blot analysis of the E-cadherin-Fc mutants using an anti–
human IgG Fc antibody demonstrated that the products
were the correct size and confirmed the results of quantita-
tion by ELISA (data not shown). To ensure that the E-cad-
herin-Fc mutants were properly folded, each of the mu-
tants was tested for the ability to support homophilic
adhesion, a function that is localized to domain 1 (16; and
see below). Additionally, all of the mutants were recog-
nized by two anti–E-cadherin mAbs in ELISA (data not
shown): E4.6, which blocks heterophilic adhesion (23), and
HECD-1, which blocks homophilic adhesion (29).
Cell–fusion protein adhesion assays were performed to
determine the function of site-directed mutants of E-cad-
herin-Fc in heterophilic adhesion to integrin aEb7–bearing
Figure 1. Structural analysis of human E-cadherin. (A) Amino acid alignment of
domain 1 of human E-cadherin with human P-cadherin and murine E- and N-cad-
herin. The positions of the b strands were determined by the Definition of Secondary
Structure of Proteins program (reference 51) and are indicated by arrows above the
alignment. The PENE sequence in the AB loop, the LDRE sequence in the EF loop,
and the DQNDN sequence in the connecting strand, which are predicted to be in-
volved in the binding calcium, are indicated by Ca21. Residues E31, D44, and E56 are
shown in boldface. (B) Ribbon diagram of the human E-cadherin domain 1 model.
Human E-cadherin was modeled based on the previously described murine E-cad-
herin crystal structure. Domain 1 of E-cadherin has seven b strands labeled A through
G. The side chains of E31 on the BC loop at the top of domain 1, of D44 on the CD
loop on the lower side of domain 1, and of E56 on the DE loop pointing upward in
the center of the domain are represented as stick diagrams with carbon atoms, shown
in black, and oxygen atoms, shown in red.1559 Taraszka et al.
cells. E-cadherin-Fc fusion protein was bound to the wells
of 96-well plates, and fluorescently labeled T cell adhesion
to E-cadherin-Fc was determined by quantitating the fluo-
rescence bound. Adhesion of the human intestinal IEL–
derived T cell line IEL-496 to immobilized wild-type
E-cadherin-Fc was dose dependent (Fig. 2, r). Maximal
adhesion (60%) to wild-type E-cadherin-Fc was achieved
with 0.02 mg of E-cadherin-Fc added per well, whereas
human IgG1, which contains the same Fc portion as the
fusion protein, did not support adhesion (Fig. 2, compare
r to j). The specificity of adhesion in this assay was con-
firmed by mAb blocking with anti-aE mAb (aE7-2) and
anti–E-cadherin mAb (E4.6), both of which blocked IEL
adhesion to E-cadherin-Fc (data not shown).
To delineate the critical loop residues of E-cadherin that
mediate adhesion to aEb7, acidic loop residues in E-cad-
herin-Fc were selected for alanine substitution based on the
human E-cadherin model (above), and mutants were tested
for their ability to support adhesion of IEL-derived T cells
(Fig. 2). D44A and wild-type E-cadherin-Fc have similar
dose–response curves, and above saturating levels of fusion
protein, 59% of IELs adhered to the D44A mutant of
E-cadherin-Fc fusion protein compared with 61% of IELs
that adhered to wild-type E-cadherin-Fc (Fig. 2 A, s and
r are overlapping in figure, P # 0.71). Thus, there was no
significant difference between IEL adhesion to the E-cad-
herin-Fc CD loop mutant D44A and wild-type. Similarly,
the DE loop mutant E56A and wild-type E-cadherin-Fc
share similar dose–response curves, and at saturating levels
E56A supported 60% of IEL adhesion compared with 57%
for wild-type (Fig. 2 B, P # 0.67). Thus, there was no sig-
nificant difference between IEL adhesion to E56A and
wild-type E-cadherin-Fc. In contrast to the CD and DE
loop mutations that preserved aEb7 adhesion to E-cad-
herin, the E31A mutation at the tip of the BC loop com-
pletely abolished detectable adhesion of IELs. No IELs
bound to the E31A mutant, compared with 56% of IELs
that bound to wild-type (Fig. 2 C, P # 0.0001).
Refinement of the Heterophilic Adhesion Site.  Although
these studies pointed to a critical role for E31 in E-cadherin
adhesion to aEb7, it is unlikely that the specificity of the in-
tegrin aEb7–E-cadherin interaction is determined by a sin-
gle residue. The contact between the two molecules most
likely involves multiple residues that determine specificity
and stabilize the interaction. Using the human E-cadherin
model (Fig. 1 B), we selected additional residues with sol-
vent-exposed side chains in the proximity of E31 for site-
directed mutagenesis. In the BC loop, residues K25, N27,
K28, K30, and K33 have solvent-exposed side chains in
close proximity to the side chain of E31 and may be im-
portant in recognition of integrin aEb7. Thus, E-cadherin-
Fc fusion proteins containing mutations of these residues to
alanine were produced and tested in adhesion to aEb7-
expressing cells. Beginning at the NH2 terminus of the BC
loop, we found that 69% of the input IELs adhered to E-cad-
herin-Fc containing the K25A mutation compared with
72% of IELs that adhered to wild-type E-cadherin-Fc (Fig.
3 A, P # 0.35). Continuing along the BC loop, mutants
N27A, K28A, and K30A supported adhesion of 58% of the
IELs compared with wild-type, which supported adhesion
of 62% of the IELs (Fig. 3, B–D; P # 0.086, 0.11, 0.014,
respectively). At the COOH-terminal end of the BC loop,
the K33A mutant supported adhesion of 60% of the IELs,
which was the same percentage of IEL adhesion supported
by wild-type E-cadherin-Fc (Fig. 3 E, P # 0.46). Thus,
there were no significant differences between IEL adhesion
to wild-type E-cadherin-Fc and E-cadherin-Fc mutants
K25A, N27A, K28A, K30, and K33A.
Recognizing that .100-fold more human placental (P)-
cadherin-Fc than E-cadherin-Fc fusion protein is required
to support IEL adhesion (2), we compared the BC loops of
these two ligands. The only differences between the BC
loop of E-cadherin and P-cadherin are residues 30, 31, and
32 (Fig. 1 A). Thus, we substituted the central three resi-
dues of the BC loop of P-cadherin (RD31T) in place of
KE31G in E-cadherin (mutant termed KEG30-32RDT) to
determine the effect on IEL adhesion. Even though both
wild-type E-cadherin and the KEG30-32RDT mutant
Figure 2. IEL adhesion to E-cadherin-Fc containing mutations of the
central acidic residue in the BC, CD, and DE loops. Serial dilutions of
culture supernatants from transient transfection with wild-type or mu-
tated E-cadherin-Fc were immobilized on microtiter plate wells coated
with goat anti–human IgG antiserum. Purified human IgG1 diluted in
culture media was used as a negative control. Adhesion of IELs was deter-
mined in the presence of HBS with 1 mM MnCl2, 1 mM MgCl2, 1 mM
CaCl2, 50 mM glucose, and 0.1% BSA, as described in Materials and
Methods. Adhesion was determined in at least two independent experi-
ments with each condition performed in triplicate. Dose–response curves
are shown as the mean percentage of IELs bound 6 1 SD for a represen-
tative experiment. (A) Effect of D44A mutation in the CD loop. (B) Ef-
fect of the E56A mutation in the DE loop. (C) Effect of E31A mutation
in the BC loop.1560 Integrin aEb7 Recognition of E-Cadherin
contain an acidic residue at position 31, the KEG30-
32RDT mutation completely abolished adhesion of IELs
(Fig. 3 F, P # 0.0001). To distinguish the role of E31 from
the flanking residues, we also constructed the conservative
E31D mutation. Surprisingly, the E31D mutation also
completely abolished detectable adhesion of IELs (Fig. 3 G,
P # 0.0001).
The FG loop is located adjacent to the BC loop at the
top of the cadherin domain, suggesting that side chains of
this loop might also participate in integrin binding (Fig. 1
B). Analysis of the human E-cadherin model revealed that
the side chains of residues S83, N86, and E89 in the FG
loop are in close proximity to the critical E31 residue in the
BC loop. E-cadherin-Fc fusion protein containing the FG
loop S83A mutation was found to support adhesion of 68%
of the IELs compared with adhesion of 72% of the IELs to
wild-type E-cadherin-Fc (Fig. 4 A, P # 0.55). E-cadherin-
Fc with the N86A mutation supported adhesion of 57% of
the IELs compared with adhesion of 53% of the IELs sup-
ported by wild-type E-cadherin-Fc (Fig. 4 B, P # 0.068).
These results indicated that the S83A and N86A mutations
did not significantly affect aEb7-dependent adhesion of IELs
to E-cadherin. E-cadherin-Fc containing the E89A muta-
tion supported adhesion of 12% of the IELs compared with
adhesion of 72% of the IELs to wild-type (Fig. 4 C), sug-
gesting that the E89A mutation substantially diminished
aEb7-dependent IEL adhesion to E-cadherin (P # 0.0001).
For easier comparison, the effect of the mutations on adhe-
sion to IELs is summarized as the percentage of adhesion
compared with wild-type (Fig. 5 A). The three mutants that
revealed the greatest effect were all located in the BC loop
and involved residue E31. These mutations completely ab-
rogated adhesion to ,2% of wild-type adhesion. In addi-
tion, E89A in the FG loop reduced heterophilic adhesion to
Figure 3. IEL adhesion to
E-cadherin-Fc BC loop mu-
tants. Adhesion was determined
in at least two independent ex-
periments in which each condi-
tion was performed in triplicate,
as described in the legend to Fig.
2. Results are shown as the mean
percentage of IELs bound 6 1
SD for a representative experi-
ment. (A) Dose–response of IEL
adhesion to K25A. (B) Dose–
response of IEL adhesion to
N27A. (C) Dose–response of
IEL adhesion to K28A. (D)
Dose–response of IEL adhesion
to K30A. (E) Dose–response of
IEL adhesion to K33A. (F)
Dose–response of IEL adhesion
to KEG30-32RDT. (G) Dose–
response of IEL adhesion to
E31D.
Figure 4. IEL adhesion to E-cadherin-Fc FG loop mutants. Adhesion
was determined in at least two independent experiments in which each
condition was performed in triplicate, as described in the legend to Fig.
2. Results are shown as the mean percentage of IELs bound 6 1 SD for
a representative experiment. (A) Dose–response of IEL adhesion to
S83A. (B) Dose–response of IEL adhesion to N86A. (C) Dose–response
of IEL adhesion to E89A.1561 Taraszka et al.
20% of wild-type. In contrast, the other mutations located
in the remainder of the BC and FG loop as well as the CD
and DE loops supported .82% of wild-type adhesion.
Additional Mutations Reduce Heterophilic Adhesion of K562-
aEb7 Transfectants to E-Cadherin.  To confirm the impor-
tance of E31 on the top of the BC loop and E89 on the FG
loop in IEL adhesion to E-cadherin-Fc and to identify ad-
ditional residues involved in heterophilic adhesion, we ex-
amined the adhesion of K562-aEb7 transfectants to the
panel of E-cadherin-Fc mutants under the same conditions
used to study heterophilic adhesion of IEL T cells. We hy-
pothesized that K562-aEb7  transfectants might identify
other residues involved in heterophilic adhesion, as K562-
aEb7 transfectants adhere less strongly to E-cadherin-Fc
under the same conditions. Similar to IEL adhesion, het-
erophilic adhesion of K562-aEb7 transfectants to immobi-
lized E-cadherin-Fc is dose dependent, with maximal ad-
hesion achieved with 0.02 mg of E-cadherin-Fc added per
well. Adhesion is specific, as ,1% of K562 mock transfec-
tants bound to E-cadherin-Fc–coated wells, and ,1% of
K562-aEb7 transfectants bound to IgG1-coated wells (data
not shown). However, mean maximal adhesion of K562-
aEb7 transfectants to wild-type E-cadherin-Fc is 30% com-
pared with mean maximal adhesion of IEL to wild-type
E-cadherin-Fc, which is 58% (data not shown).
Heterophilic adhesion of K562-aEb7 transfectants to
mutants E31A, E31D, and KEG30-32RDT was not de-
tectable, confirming the findings in adhesion to in vitro–
cultured IEL T cells expressing aEb7 (Fig. 5 B). E-cad-
herin-Fc containing K25A and K33A mutations in the BC
loop supported adhesion similar to wild-type: 87% (P #
0.0113) and 104% (P # 0.36), respectively, as a percentage
of adhesion to wild-type E-cadherin (Fig. 5 B). BC loop
mutants N27A, K28A, and K30A only partially supported
adhesion of K562-aEb7 transfectants: 57% (P # 0.0001),
79% (P # 0.0001), and 53% (P # 0.0001), respectively, as
a percentage of adhesion to wild-type E-cadherin (Fig. 5
B). Thus, K562-aEb7 transfectants identified additional BC
loop mutations with statistically significant differences in
the ability to support heterophilic adhesion compared with
wild-type, namely N27A, K28A, and K30A. Mutants con-
taining the D44A change in the CD loop and the E56A
change in DE loop supported heterophilic adhesion to
K562-aEb7 similar to wild-type: 105% (P  # 0.62) and
102% (P # 0.40), respectively, like the situation for these
mutations in adhesion to IELs. FG loop mutations S83A
and N86A partially supported heterophilic adhesion to
K562-aEb7: 80% (P # 0.0001) and 86% (P # 0.0017), re-
spectively, as a percentage of adhesion to wild-type E-cad-
herin-Fc (Fig. 5 B). In contrast, FG loop mutant E89A did
not support detectable adhesion, confirming the finding
with adhesion to IELs (Fig. 5 B). In summary, the K562-
aEb7 transfectants confirmed the role of mutations noted
for adhesion of IELs and identified several additional mu-
tants with smaller but statistically significant differences in
the ability to support heterophilic adhesion compared with
wild-type (N27A, K28A, K30A, S83A, and N86A). For a
conservative interpretation, we emphasize mutations N27A
and K30A, as they resulted in the largest (.40%) reduction
in aEb7-dependent adhesion (Fig. 5 B).
Location of aEb7 Adhesion Site on E-Cadherin.  We analyzed
the human E-cadherin model examining the location of
residues affecting or not affecting adhesion of aEb7-express-
ing cells to E-cadherin-Fc. As shown in the ribbon diagram
of domain 1 of E-cadherin, the side chains of residues K25
and K33 on the BC loop and E56 on the DE loop point in
approximately the same direction away from the sheet
formed by the D, E, and B strands (Fig. 6 A). Mutation of
residues K25, K33, and E56 to alanine in E-cadherin-Fc
did not affect heterophilic adhesion to IELs or K562-aEb7
transfectants, suggesting that the integrin does not approach
E-cadherin at the DEB sheet. The side chains of residues
D44 on the CD loop and S83 and N86 on the FG loop are
Figure 5. Heterophilic adhesion of IELs (A) and K562-aEb7 (B) to E-cad-
herin-Fc mutants. Using adhesion to saturating amounts of E-cadherin-
Fc, the mean adhesion to each mutant is expressed relative to adhesion to
wild-type E-cadherin-Fc (% cells bound to mutant E-cadherin-Fc/% cells
bound to wild-type E-cadherin-Fc 3 100). Adhesion to wild-type E-cad-
herin-Fc is shown as 100%. Adhesion above the saturating dose was cho-
sen to minimize the effect of any errors in quantitation of the fusion pro-
tein. Mutation KEG30-32RDT is abbreviated KEG. The loop containing
the mutated residues is marked below the lines. Results are shown as the
mean 6 1 SD of at least two independent experiments in which each con-
dition was performed in triplicate. A two-sided t test was used to compare
the mean value of IEL adhesion to each E-cadherin-Fc mutant with the
mean value of IEL adhesion to wild-type E-cadherin-Fc. (A) IEL adhesion
to the panel of E-cadherin-Fc mutants. Statistically significant differences
are observed for KEG30-32RDT (P # 0.0001), E31A (P # 0.0001),
E31D (P # 0.0001), and E89A (P # 0.0001). (B) K562-aEb7 adhesion to
the section of E-cadherin-Fc mutants. Statistically significant differences
are observed for N27A (P # 0.0001), K28A (P # 0.0001), K30A (P #
0.0001), KEG30-32RDT (P # 0.0001), E31A (P # 0.0001), E31D (P #
0.0001), N86A (P # 0.0017), and E89A (P # 0.0001).1562 Integrin aEb7 Recognition of E-Cadherin
located on the other side of E31 and point away from the
CFG face (Fig. 6 A). Mutations D44A, S83A, and N86A
did not have a substantial effect on heterophilic adhesion to
IELs or K562-aEb7 transfectants, suggesting that the inte-
grin does not approach E-cadherin at the CFG face. In
contrast, the side chains of residues N27, K28, K30, and
E31 on the BC loop as well as E89 on the FG loop are
highly solvent-exposed at the top of the molecule on the
face formed by the BC and FG loops (Fig. 6 A). Mutation
of E31 and E89 severely diminished heterophilic adhesion
of both IEL and K562-aEb7 transfectants. Mutations
N27A, K28A, and K30A had statistically significant reduc-
tions in adhesion to K562-aEb7 transfectants, and N27A
and K30A reduced K562-aEb7 transfectant adhesion
.40%.
A surface diagram of E-cadherin in the same orientation
as the ribbon diagram in Fig. 6 A more clearly demonstrates
the location of the side chains that were mutated (Fig. 6 B).
The side chains of residues N27, K30, E31, and E89,
which are involved in adhesion to aEb7, are shown in red.
Despite the fact the implicated residues come from differ-
ent loops, they are located on the same face (Fig. 6 B).
Residues that do not substantially affect adhesion to aEb7
are shown in blue. Rotation of the surface diagram 1808 on
a vertical axis demonstrates that residues on the opposite
side are not involved in adhesion to aEb7 (Fig. 6 C).
Therefore, it is likely that the integrin aEb7 approaches do-
main 1 of human E-cadherin at the face formed by the BC
and FG loops.
Analysis of the three-dimensional human E-cadherin
model suggests that the side chains of residues N27, K30,
and E31 protrude upward and could directly interact with
the integrin (partially illustrated in Fig. 6 A). Residue E89
likely forms interactions with one or both residues, S26 and
K28. E89 has the potential to form a salt bridge with the
main chain amide of K28, similar to the E89/R28 pair ob-
served in murine E-cadherin (19). E89 might also form a
hydrogen bond with residue S26. These interactions would
serve to stabilize the BC loop that presents residues N27,
K30, and E31 for integrin recognition. In summary, muta-
tional analyses of the NH2-terminal domain of human
E-cadherin identified a localized group of exposed residues
at the top of the domain that are likely to be part of the in-
tegrin aEb7 binding site either by directly binding to the
integrin or by supporting the conformation of the integrin
binding residues.
Homophilic Adhesion of E-Cadherin-Fc Mutants.  We tested
the ability of E-cadherin-Fc and its mutants to support ho-
mophilic adhesion of E-cadherin–expressing MCF-7 breast
epithelial cells. Adhesion of MCF-7 cells to E-cadherin-Fc
was dose dependent, with maximal adhesion of 40% of cells
bound with 0.02 mg of E-cadherin-Fc added per well (Fig.
7, r), whereas adhesion to human IgG1 was not observed
(Fig. 7, j). Confirming the specificity of this adhesion as-
say, we found that the adhesion of MCF-7 cells to E-cad-
herin-Fc was blocked by anti–E-cadherin mAbs HECD-1
and SHE78-7, but not by isotype-matched control mAbs
against aEb7, aE7-1, and aE7-2 (data not shown), and the
interaction did not require the presence of magnesium or
manganese.
The E-cadherin-Fc mutants were tested in homophilic
adhesion to MCF-7 epithelial cells to demonstrate that the
mutants were functionally folded and to determine whether
the heterophilic adhesion site for aEb7 is distinct from the
homophilic site for E-cadherin. E-cadherin-Fc mutations
that completely abrogated IEL adhesion did not affect ho-
mophilic adhesion (Fig. 7). E31A E-cadherin-Fc supported
homophilic adhesion of 41% of the MCF-7 cells (Fig. 7 A),
KEG30-32RDT E-cadherin-Fc supported homophilic ad-
hesion of 38% of the MCF-7 cells (Fig. 7 B), and E31D
E-cadherin-Fc supported homophilic adhesion of 41% of
the MCF-7 cells (Fig. 7 C), compared with adhesion of
44% of the MCF-7 cells to wild-type E-cadherin-Fc. Thus,
there were no significant differences between MCF-7 ho-
mophilic adhesion to wild-type E-cadherin-Fc and E-cad-
herin-Fc mutants E31A, KEG30-32RDT, and E31D, de-
Figure 6. Ribbon and surface
diagrams of domain 1 of E-cad-
herin demonstrating the location
of mutated residues. (A) Ribbon
diagram of E-cadherin domain 1.
The side chains of residues in-
volved in adhesion to aEb7 are
shown with stick diagrams in red.
Mutation of side chains shown in
blue did not diminish adhesion
to aEb7 or diminished adhesion
to aEb7 ,20%. (B) Surface dia-
gram of E-cadherin domain 1 in
the same orientation as A. Resi-
dues involved in adhesion to
aEb7 are shown in red, and resi-
dues that did not affect adhesion
to aEb7 are shown in blue. (C)
Surface diagram of E-cadherin
domain 1 rotated z1808 on a
vertical axis from B.1563 Taraszka et al.
spite the effect these mutations revealed in heterophilic
adhesion. The ability of these E-cadherin mutants to func-
tion in homophilic adhesion confirms that these loop muta-
tions did not affect proper folding of the cadherin domain
and that the heterophilic aEb7 adhesion site is distinct from
the homophilic E-cadherin adhesion site.
Fig. 8 summarizes the effect of the mutations on ho-
mophilic adhesion to saturating amounts of mutated E-cad-
herin-Fc fusion proteins relative to adhesion to wild-type
E-cadherin-Fc. Mutants K25A and N27A located at the
beginning of the BC loop exhibit a mild reduction in ho-
mophilic adhesion compared with wild-type E-cadherin-Fc.
Mutant K25A supports 76% of the homophilic adhesion
observed to wild-type E-cadherin-Fc (P # 0.0003), and
mutant N27A supports 62% of the homophilic adhesion
observed to wild-type E-cadherin-Fc (P # 0.0001). There
were no significant differences between the adhesion of the
other E-cadherin-Fc BC loop mutants (K28A, K30A, and
K33A) and wild-type. Mutants K28A, K30A, and K33A
supported homophilic adhesion 94, 99, and 91% as well as
wild-type E-cadherin, respectively. Mutants D44A in the
CD loop and E56A in the DE loop supported homophilic
adhesion 94 and 90% as well as wild-type E-cadherin-Fc.
Mutants S83A and N86A on the FG loop and N86A also
supported wild-type levels of homophilic adhesion: 105
and 93%, respectively. Homophilic adhesion supported by
mutants D44A, E56A, S83A, and N86A is not significantly
different from adhesion supported by wild-type. In con-
trast, E-cadherin-Fc containing the E89A mutation on the
G strand supported only 2% of the homophilic adhesion
observed for wild-type E-cadherin (P # 0.0001), similar to
its inability to support heterophilic adhesion. As the E89A
mutant was efficiently secreted and recognized by two anti-
E-cadherin mAbs, it remains likely that it is properly folded
and has a role in both heterophilic and homophilic adhesion.
Although we have not specifically addressed the ho-
mophilic adhesion site, several of the residues we mutated
have been implicated in homophilic adhesion in previous
studies. Mutational analyses localize the homophilic bind-
ing site to domain 1 of E-cadherin and homophilic adhe-
sion specificity determining residues to serine residues on
either side of the HAV sequence at the end of the F strand:
S78 and S83 (16). Simultaneous mutation of both S78 and
S83 in E-cadherin to the corresponding residues in P-cad-
herin does not abolish calcium-dependent homophilic cell
aggregation, but allows cadherin transfectants to aggregate
with both E- and P-cadherin (16). In agreement, our re-
sults showed that point mutation of S83A does not dimin-
ish homophilic adhesion. The homophilic adhesion inter-
face suggested by the adhesion dimer in the N-cadherin
domain 1 crystal structure includes interactions between
the C strand and C9 strand (prime indicates that the struc-
ture comes from the adjacent molecule), reciprocal contact
between the DE loop to FG9 loop, and the CD loop to
CD9 loop interactions (18). D44 is the only residue we
mutated that is present at the homophilic adhesion inter-
Figure 7. Homophilic adhesion of MCF-7 cells to E-cadherin-Fc mu-
tants E31A, KEG30-32RDT, and E31D. Serial dilutations of wild-type
and mutated E-cadherin and IgG1 were immobilized on plates coated
with goat anti–human IgG antiserum. Homophilic adhesion assays with
E-cadherin–expressing MCF-7 cells were performed in HBS with 1 mM
CaCl2, 50 mM glucose, and 0.1% BSA, as described in Materials and
Methods. Results are shown as the mean percentage of MCF-7 cells
bound 6 1 SD and are representative of at least two independent experi-
ments in which each condition was performed in triplicate. (A) Ho-
mophilic adhesion to KEG30-32RDT (KEG). (B) Homophilic adhesion
to E31A. (C) Homophilic adhesion to E31D.
Figure 8. Homophilic adhesion of MCF-7 cells to E-cadherin-Fc mu-
tants. Adhesion of MCF-7 cells to saturating amounts of mutated E-cad-
herin-Fc is expressed relative wild-type E-cadherin-Fc, as described in the
legend to Fig. 5. Results are shown as the mean 6 1 SD of two indepen-
dent experiments in which each condition was performed in triplicate.
Using a two-sided t test, statistically significant differences were observed
between homophilic adhesion to wild-type E-cadherin-Fc and K25A
(P # 0.0003), N27A (P # 0.0001), and E89A (P # 0.0001).1564 Integrin aEb7 Recognition of E-Cadherin
face. Mutation of D44A did not diminish homophilic ad-
hesion, suggesting that either the loss of D44’s contribu-
tions is not significant enough to diminish homophilic
adhesion because of the complexity of the homophilic ad-
hesive interaction or the adhesion dimer seen in the crystal
structure may not be the physiological interface.
Previous studies suggest that homophilic adhesion re-
quires dimerization (30, 31). However, controversy exists
over which part of the cadherin domain is involved in cis-
dimerization (18–20). In our study, mutation of residues
K25, N27, and E89 significantly diminished homophilic
adhesion. As E-cadherin-Fc mutants K25A and N27A ex-
hibit near wild-type adhesion to IELs, they are most likely
functionally folded. As can be observed in Fig. 6 B, the res-
idues that disrupt homophilic adhesion are located on the
same face. These residues could affect homophilic adhesion
by directly being part of the homophilic binding site or in-
directly by contributing to cis-dimerization of E-cadherin.
Residues K25, N27, and E89 are located at the cis-dimer
interface observed in the murine N-cadherin domain 1
crystal structure (18) and have the potential to support cis-
dimerization. Thus, we propose that mutations K25, N27,
and E89 indirectly affect homophilic adhesion by interfer-
ing with cis-dimerization. This interpretation supports a
physiological role for the cis-dimer in homophilic adhesion.
Discussion
A well-defined feature of integrin ligands is the presence
of an aspartic acid or glutamic acid residue that is essential
for integrin adhesion. The critical acidic residue in the
ligand may provide a coordination site for the divalent cat-
ion that is essential for integrin adhesion (6). Our first ap-
proach was to mutate solvent-exposed acidic residues on
the various loops of human E-cadherin to localize integrin
recognition to a particular loop. We selected potential resi-
dues from our model of human E-cadherin based on the
crystal structure of murine E-cadherin (19). Mutational
analyses of the exposed acidic residues on the BC, CD, and
DE loops localized the aEb7 binding site to E31 in the BC
loop of domain 1. This result is consistent with a previous
analysis of acidic loop residues in murine E-cadherin using
aEb7-expressing cells adhering to L cell transfectants ex-
pressing murine E-cadherin mutants (32). We further ana-
lyzed the role of the BC loop in determining the specificity
of the E-cadherin interaction with aEb7 with the KEG30-
32RDT mutation that substitutes P- for E-cadherin resi-
dues at the tip of the BC loop. Failure of this mutant to
support heterophilic cadherin adhesion indicates that the
central residues in the BC loop of P-cadherin cannot sup-
port adhesion of aEb7. In contrast, substitution of the CD
loops of MAdCAM-1 and VCAM-1 does not dramatically
affect integrin recognition. Previous studies demonstrated
that the CD loop residues of ICAM-1, GIET, can substi-
tute for the CD loop of VCAM-1, QIDS, in a cell–cell
a4b1-dependent adhesion assay (33). Additionally, previous
studies demonstrated that the CD loop residues of MAd-
CAM-1, GLDTS, can substitute for the CD loop of
VCAM-1, QIDSP, in mediating a4b1-mediated cell spread-
ing on and a4b7-cell adhesion to VCAM-Fc (34). The dif-
ference between this study and previous work emphasizes
that the integrin aEb7 displays extreme specificity for the
specific acidic residue at the adhesion site and for the spe-
cific residues flanking the acidic residue.
To determine whether the lack of adhesion to the
KEG30-32RDT mutant was due to the conservative
change in the acidic residue or due to the side chains of
the flanking residues, we made the E31D mutation. Rele-
vant mutations of other integrin ligands have been tested
in adhesion. Mutation of the critical acidic residue D40 in
CD loop of domain 1 of soluble, recombinant VCAM-1
to glutamate did not diminish cell adhesion via a4b1 (35)
and resulted in a ,50% reduction in cell spreading via
a4b1 (34). However, the D40E mutation in recombinant
VCAM-1 and the homologous D41E mutation in recom-
binant murine MAdCAM-1 resulted in an almost com-
plete loss of cell adhesion via a4b7 (34). Mutation of the
critical acidic residue on the C strand of domain 1 of
ICAM-1 E34D almost completely abrogated binding to
aLb2 in a cell-free system (36). These previous studies sug-
gest that changing the critical acidic residue to another
acidic residue has little affect on a4b1 recognition, but al-
most entirely abrogates recognition by a4b7 and aLb2.
Here, the E31D E-cadherin-Fc mutation abrogated adhe-
sion of IELs and K562-aEb7 transfectants, suggesting that
aEb7 has remarkably fine specificity for the length of the
side chain of glutamic acid residue 31 in E-cadherin (Fig.
5). Analysis of the murine E-cadherin crystal structure re-
veals that there is one hydrogen bond between the main
chain carbonyl group of residue 28 (R28 in murine, and
K28 in human E-cadherin) and the main chain amide
group of residue 32 (T32 in murine, and G32 in human
E-cadherin). It is likely that this hydrogen bond will make
the tip of the BC loop assume a rigid conformation so that
the key residue E31 can be posed in the correct configura-
tion for binding to the integrin, potentially the MIDAS
metal center. Moreover, we have also noticed a minihy-
drophobic core between the BC and FG loops, centered
around V34, which should further stabilize the BC loop.
This minihydrophobic core includes V88, A80, and Y36,
as well as those aliphatic portions of other residues like
K28; all of these residues are conserved. There is one more
hydrogen bond in this region between the hydroxyl group
of Y36 and the main chain amide group of S26. Although
the overall atomic mobility of BC loop in the murine E-
and N-cadherin crystal structure is high with respect to the
core (18, 19), these interactions serve to make the long BC
loop rigid with respect to itself. From an energetic point of
view, a rigid loop is more favorable during the ligand
binding interaction. This may explain why the conserva-
tive E31D mutation abolishes adhesion. If the key binding
motif is in a very delicate conformation designed for inte-
grin binding, even the size of the one methyl group differ-
ence between glutamate and aspartate could be significant.
Similar hydrogen bonding systems that surround key acidic
integrin binding residues and help rigidify the binding motif1565 Taraszka et al.
have been reviewed for other IgSF ligands of both A do-
main and non–A domain containing integrins (37).
Our mutational analyses of selected residues with sol-
vent-exposed side chains towards the top of E-cadherin
domain 1 revealed that the side chains of N27, K30, E31,
and E89 are important for integrin aEb7 recognition. Mod-
eling of the position of these side chains in human E-cad-
herin revealed that they are all located on the same face
formed by the BC and FG loops at the top of domain 1
(Fig. 6 B). As previously discussed, these residues may di-
rectly interact with the integrin aEb7 or may be important
in maintaining the conformation of the residues that di-
rectly contact the integrin.
The integrin ligands ICAM-1, -2, -3, VCAM-1, and
MAdCAM-1 belong to the IgSF. Although the tenth type
III repeat of fibronectin and E-cadherin lack the sequence
homology and conserved disulfide bonds to be considered
an Ig fold, both of these domains share an Ig-like b sand-
wich topology consisting of two b sheets made up of three
or four antiparallel b strands (18, 19, 38). This b sandwich
topology appears to be a conserved scaffold in integrin rec-
ognition. However, our studies emphasize that integrins
use different exposed surfaces for recognition of different
ligands. In MAdCAM-1 and VCAM-1, the critical acidic
residue is present at the tip of the CD loop that protrudes
from the side on the lower half of domain 1 (Fig. 9; 10–13,
28, 33, 34, 39–41). In contrast, in the ICAMs the acidic
residue critical for integrin recognition is located at the end
of the C strand on a flat recognition surface located on the
lower side of domain 1 (Fig. 9; 14, 15, 36, 42–46). The
binding site for integrins a5b1,  aIIbb3, and aVb3 on fi-
bronectin is the RGD sequence on an extended FG loop of
the tenth type III repeat (Fig. 9; 38, 47). In contrast, aEb7
recognizes E-cadherin at the top of the Ig-like cadherin
first domain (Fig. 9). The critical acidic residue E31 is lo-
cated at the very tip of the outwardly extended BC loop,
and the integrin recognition surface contains residues from
the BC and the adjacent FG loop. The local conformation
around the critical acidic residue E31 in E-cadherin is most
similar to the conformation of the corresponding FG loop
in fibronectin. In conclusion, integrin recognition of E-cad-
herin extends the general paradigm that Ig-like folds serve
as a scaffold for integrin recognition, but is unique in using
the BC loop at the top of the domain (Fig. 9).
Importantly, while the three mutants involving E31
(E31A, KEG30-32RDT, and E31D) did not support de-
tectable heterophilic adhesion, they did support homophilic
adhesion of cells expressing wild-type E-cadherin. These
results are the first direct evidence that the heterophilic ad-
hesion site on E-cadherin for aEb7 is distinct from the ho-
mophilic E-cadherin–E-cadherin adhesion site. This finding
is consistent with previous studies examining the ho-
mophilic adhesion site and localizing it to the face formed
by the C strand, D strand, and FG loop and in particular to
residues at the COOH terminus of the F strand and in the
FG loop (16, 18, 48). As the E-cadherin residues critical for
heterophilic adhesion to aEb7 are distinct from those re-
quired for homophilic adhesion, it is possible to block het-
erophilic adhesion selectively while preserving E-cadherin’s
homophilic function. The analyses of aEb7 recognition of
E-cadherin suggest that blockade of this interaction may be
similar in molecular terms to that of other integrin–IgSF in-
teractions. The current data provide both the conceptual
basis and suitable assay systems to identify therapeutic inhib-
Figure 9. Comparison of integrin recognition sites in E-cadherin, fibronectin, MAdCAM-1, and ICAM-1. Ribbon diagrams of domain 1 of murine
E-cadherin (Protein Database accession no. 1EDH; reference 19), the tenth type III repeat of human fibronectin (accession no. 1FNF; reference 36), do-
main 1 of human MAdCAM-1 (accession no. 1BQS; reference 10), and domain 1 of human ICAM-1 (accession no. 1IC1; reference 41) are shown. The
location of the side chains of acidic residues critical for integrin adhesion are shown with stick diagrams using black for carbon atoms, red for oxygen at-
oms, and blue for nitrogen atoms. Where applicable, the loop involved in integrin recognition is highlighted in orange. The location of the integrin rec-
ognition sites in MAdCAM-1 and ICAM-1 is also representative of VCAM-1 and ICAM-2/ICAM-3, respectively. ICAM-1, ICAM-2, VCAM-1, and
MAdCAM-1 all have an extra disulfide bond, not characteristic of the Ig fold, between the BC loop and the FG loop or F strand. The conserved disulfide
bond of Ig folds and the extra disulfide bond between the BC and FG loops are shown in yellow in the MAdCAM-1 and ICAM-1 structures.1566 Integrin aEb7 Recognition of E-Cadherin
itors. Our data suggest that the potential exists to design
therapeutics that selectively block the E-cadherin–aEb7 in-
teraction and do not disrupt E-cadherin homophilic adhe-
sion. Integrin aEb7 is expressed on nearly all T cells local-
ized in the epithelium, as well as on certain mast cells and
dendritic cells (22, 49, 50). Agents that block the interac-
tion of aEb7-expressing cells with E-cadherin–expressing
epithelium could be useful therapeutics in mucosal inflam-
matory conditions such as inflammatory bowel disease.
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